Skip Navigation

ACS is committed to helping combat the global COVID-19 pandemic with initiatives and free resources. Learn More

Ian Churcher

Ian Churcher

Ian Churcher is currently VP of Drug Discovery at BenevolentBio, a bioscience subsidiary of BenevolentAI, where he is applying a range of artificial intelligence approaches to all phases of drug discovery and development. Prior to this, for 5 years, he was Head of the Protein Degradation Discovery Performance Unit at GSK, one of the pioneering groups who, working with Prof Craig Crews, demonstrated the application of Protac approaches to drug discovery. Ian has previously held a number of drug discovery & medicinal chemistry roles in GSK and Merck where he has always championed novel technologies and strategies to discover drugs. Ian was also a Visiting Professor in the Department of Chemistry at the University of Oxford from where he also holds MA and DPhil degrees.